Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CA 125 in biological fluids.

R Molina1, X Filella, J Jo

  • 1Laboratory of Clinical Biochemistry, Cancer Unit, Division of Pulmonary Diseases, School of Medicine, Bareclona-Spain.

The International Journal of Biological Markers
|May 6, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to Liccardi et al. Why Are Allergens Not Detected in Bronchoalveolar Lavage Fluid?

Journal of investigational allergology & clinical immunology·2019
Same author

Design optimization of a fast-neutron detector with scintillating fibers for triton burnup experiments at fusion experimental devices.

The Review of scientific instruments·2019
Same author

Allergens Are Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy.

Journal of investigational allergology & clinical immunology·2019
Same author

Knowledge, actual and potential use of HIV self-sampling testing kits among MSM recruited in eight European countries.

HIV medicine·2018
Same author

The COBATEST network: monitoring and evaluation of HIV community-based practices in Europe, 2014-2016.

HIV medicine·2018
Same author

A pilot study of planar coil based magnetic stimulation using acute hippocampal slice in mice.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2017
Same journal

The diagnostic and predictive value of miR-145-3p in gastric cancer and its regulation of gastric cancer progression via targeting CREB1.

The International journal of biological markers·2026
Same journal

PFKP: A biomarker for prognosis, response to treatment and immune function of breast cancer.

The International journal of biological markers·2026
Same journal

Luminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze-thaw stability.

The International journal of biological markers·2026
Same journal

Expression of concern: "RIPK4 is Downregulated in Poorly Differentiated Tongue Cancer and is Associated with Migration/Invasion and Cisplatin-Induced Apoptosis".

The International journal of biological markers·2026
Same journal

Association of NF-kappaBIA rs696 gene polymorphism with breast cancer risk in Bangladeshi women: A case-control study.

The International journal of biological markers·2026
Same journal

Circulating tumor cells and tumor-derived cell-free DNA in cancer management: Clinical evidence, limitations, and future directions.

The International journal of biological markers·2026
See all related articles

Cancer antigen 125 (CA 125) is a tumor marker useful for monitoring ovarian and lung cancers. While not specific, its levels in serum and fluids aid in detecting recurrence and monitoring treatment effectiveness.

Area of Science:

  • Biochemistry
  • Oncology
  • Clinical Diagnostics

Background:

  • CA 125 is synthesized by normal and malignant cells, particularly those derived from müllerian epithelia.
  • Abnormal CA 125 levels can be detected in various bodily fluids and serum, making it a versatile marker.

Purpose of the Study:

  • To evaluate the utility of CA 125 as a tumor marker in different cancers.
  • To assess the sensitivity and applications of CA 125 in ovarian and lung cancer detection and monitoring.

Main Methods:

  • Analysis of CA 125 synthesis in normal and malignant cells.
  • Correlation of serum CA 125 levels with disease presence (benign vs. malignant).
  • Evaluation of CA 125 sensitivity in ovarian and lung cancer based on stage and histology.

Related Experiment Videos

Main Results:

  • CA 125 sensitivity in ovarian cancer ranges from 40-95%, varying by stage and histology, and is effective for recurrence detection (80% sensitivity) and therapy monitoring.
  • CA 125 sensitivity in lung cancer is lower (39% locoregional, 69% metastatic) but useful for prognosis and monitoring, especially in adenocarcinomas and large cell lung cancer.

Conclusions:

  • CA 125 is a valuable tumor marker for ovarian and lung cancers, aiding in early recurrence detection, therapy monitoring, and prognosis.
  • Despite not being entirely specific, CA 125's correlation with disease stage and histology enhances its clinical utility in oncology.